

# Roche to pay \$7.1 bn for Telavant Holdings

October 23 2023

---



Credit: Anna Shvets from Pexels

Swiss pharmaceutical group Roche said Monday it will pay \$7.1 billion to buy Telavant Holdings, a group developing new treatments for inflammatory bowel diseases.

The company is currently owned by British laboratory Roivant and

American pharma giant Pfizer.

The [agreement](#) includes the "development, manufacturing and commercialization rights in the US and Japan" for the antibody RVT-3101, used for treating people suffering with inflammatory bowel disease [ulcerative colitis](#) and Crohn's disease.

The antibody is currently undergoing [clinical trials](#).

Under the deal, Roche will pay a purchase price of \$7.1 billion upfront and a near-term milestone payment of \$150 million.

Roche said the antibody also has "potential to be applied in multiple other diseases" and it wants to make it available to patients "as quickly as possible".

"We strongly believe this novel TL1A directed antibody has the transformational potential to make a significant difference for patients living with [inflammatory bowel disease](#) and potentially other diseases," said Thomas Schinecker, CEO of Roche.

Telavant was created last year by Roivant—which holds 75 percent of the shares—and Pfizer, which owns 25 percent.

© 2023 AFP

Citation: Roche to pay \$7.1 bn for Telavant Holdings (2023, October 23) retrieved 28 April 2024 from <https://medicalxpress.com/news/2023-10-roche-pay-bn-telavant.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.